49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

diseases per page:

Showing 1 to 10 of 946 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05278663 (ClinicalTrials.gov)	April 30, 2022	4/3/2022	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythema ...	A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Asses ...	Lupus Erythematosus, Systemic	Drug: E6742;Other: Placebo	Eisai Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	24	Phase 1/Phase 2	Japan
2	NCT05247203 (ClinicalTrials.gov)	April 2022	26/1/2022	Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus	A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept ...	Systemic Lupus Erythematosus	Biological: Telitacicept;Drug: standard therapy	RemeGen Co., Ltd.	NULL	Not yet recruiting	18 Years	65 Years	All	75	Phase 1	China
3	NCT04893161 (ClinicalTrials.gov)	March 31, 2022	16/5/2021	A Model About the Response of Belimumab in SLE	A Model to Early Predict the Response of Belimumab Treatment in the Patients With Systemic Lupus Ery ...	Systemic Lupus Erythematosus	Drug: Belimumab	First Affiliated Hospital Xi'an Jiaotong University	NULL	Not yet recruiting	18 Years	N/A	All	72	Phase 4	NULL
4	NCT05262686 (ClinicalTrials.gov)	March 10, 2022	22/2/2022	Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic L ...	Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic L ...	Systemic Lupus Erythematosus	Drug: Belimumab;Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	70 Years	All	10	Phase 3	China
5	EUCTR2019-003406-27-DK (EUCTR)	09/03/2022	04/03/2021	A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with modera ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef ...	Systemic lupus erythematosus(SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Name: Dapirolizumab pegol Product Code: CDP7657 INN or Proposed INN: Dapirolizumab pegol Other ...	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;Serbia;Portugal;Philippines;Taiwan;Greece;Spain;Chile;Colombia;Italy;France;Peru;Austr ...
6	EUCTR2019-003407-35-ES (EUCTR)	09/03/2022	17/01/2022	A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with modera ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef ...	Systemic lupus erythematosus(SLE) MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: ...	Product Name: Dapirolizumab pegol Product Code: CDP7657 INN or Proposed INN: dapirolizumab pegol Other ...	UCB Biopharma SRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;Serbia;Portugal;Czechia;Taiwan;Hong Kong;Greece;Spain;Austria;United Kingdom;Italy;Fra ...
7	NCT05236491 (ClinicalTrials.gov)	March 2022	10/2/2022	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases	Rheumatoid Arthritis;Autoimmune Rheumatologic Disease;Systemic Lupus Erythematosus;Systemic Vasculit ...	Biological: COVID-19 vaccine	Paul R Fortin	Canadian Institutes of Health Research (CIHR)	Not yet recruiting	18 Years	N/A	All	287	Phase 2/Phase 3	NULL
8	NCT05123586 (ClinicalTrials.gov)	February 28, 2022	16/11/2021	A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemi ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinic ...	Systemic Lupus Erythematosus	Drug: LY3361237;Drug: Placebo	Eli Lilly and Company	NULL	Not yet recruiting	18 Years	65 Years	All	90	Phase 2	United States;Argentina;Czechia;Mexico;Poland;Puerto Rico;Russian Federation;Ukraine
9	EUCTR2020-004047-86-HU (EUCTR)	28/02/2022	23/12/2021	A Study of ALPN-101 in Active Lupus	A Randomised, Double-Blind, Placebo-controlled study of ALPN-101 in Systemic Lupus Erythematosus	Systemic lupus erythematosus(SLE) MedDRA version: 21.1;Level: PT;Classification code 10042946;Term: ...	Product Code: ALPN-101 INN or Proposed INN: Acazicolcept Other descriptive name: ALPN-101	Alpine Immune Sciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 2	France;United States;Taiwan;Hungary;Spain;Poland;Russian Federation;Germany;Korea, Republic of
10	JPRN-jRCT2011210069	15/02/2022	05/02/2022	A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With ...	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy ...	Systemic Lupus Erythematosus	ArmA:BMS-986256 30mg QD ArmB:BMS-986256 10mg QD ArmC:BMS-986256 2.5mg QD ArmD:Placebo QD	Ranganathan Usha	NULL	Recruiting	>= 20age old	<= 70age old	Both	20	Phase 2	Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Mexico;Poland;Romania;Spain;Taiwan; ...

First Previous1 2 3 4 5…95Next Last